NEW APPROACHES OF MORFOFUNKTIONAL PHARMACOLOGICAL CORRECTION OF VIOLATIONS OF CARDIOVASCULAR SYSTEM IN EXPERIMENTAL PREECLAMPSIA
Autor: | V.V. Gureev |
---|---|
Rok vydání: | 2016 |
Předmět: |
medicine.medical_specialty
business.industry General Medicine RM1-950 medicine.disease endotelioprotektory endothelial dysfunction Preeclampsia ADMA preeclampsia rats Internal medicine embryonic structures medicine Cardiology Therapeutics. Pharmacology Endothelial dysfunction business reproductive and urinary physiology |
Zdroj: | Research Results in Pharmacology, Vol 2, Iss 3, Pp 11-27 (2016) Research Results in Pharmacology 2(3): 11-27 |
Popis: | Experimental Modeling ADMA-like preeclampsia administration to rats was performed by Nnitro-L-arginine methyl ester, from 14 to 20 days of pregnancy. The animals were observed increase in blood pressure, proteinuria, impaired microcirculation in the placenta, the violation of the regulation of vascular tone and destructive changes in the placenta of ischemic origin. Introduction of tetrahydrobiopterin, a selective inhibitor of arginase II of, recombinant erythropoietin, tadalafil, erythromycin, azithromycin, and playback systems polivitaminnomineralnyh distant ischemic preconditioning resulted in a pronounced correction of morphological and functional disorders arise when modeling the experimental preeclampsia. This was reflected in the reduction of blood pressure, reduction of proteinuria, increase of microcirculation in the placenta, the restoration of vasodilator function of blood vessels and prevent destructive phenomena in the placenta compared with a group of untreated animals, increasing the concentration of NO end-metabolites in plasma. These data suggest a pronounced correction of morphological and functional disorders arise when modeling ADMA-like preeclampsia study medication and the prospects for further research to find new drugs have endoteleoprotektivnymi properties for correcting the second half of pregnancy preeclampsia. |
Databáze: | OpenAIRE |
Externí odkaz: |